Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 1/20 | 0.52 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.52 |
| ▸ | TGM2 | P21980 | 14/20 | 0.51 |
| ▸ | F13A1 | P00488 | 2/20 | 0.47 |
| ▸ | TGM1 | P22735 | 2/20 | 0.47 |
| ▸ | TLR2 | O60603 | 1/20 | 0.46 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.46 |
| ▸ | TGM6 | O95932 | 1/20 | 0.46 |
| ▸ | KLK7 | P49862 | 2/20 | 0.45 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19708135 | 1.00 | ITGB3 (0.52) | ITGB3ITGA2BTGM2F13A1TGM1 | |
| SCHEMBL21009949 | 1.00 | ITGB3 (0.52) | ITGB3ITGA2BTGM2F13A1TGM1 | |
| SCHEMBL22694079 | 0.99 | ITGB3 (0.51) | ITGB3ITGA2BTGM2F13A1TGM1 | |
| SCHEMBL20975607 | 0.95 | ITGB3 (0.52) | ITGB3ITGA2BTGM2F13A1TGM1 | |
| SCHEMBL22582335 | 0.92 | ITGB3 (0.49) | ITGB3ITGA2BTGM2F13A1TGM1 | |
| SCHEMBL26120901 | 0.86 | TGM2 (0.58) | ITGB3ITGA2BTGM2F13A1TGM1 | |
| SCHEMBL26120906 | 0.86 | TGM2 (0.58) | ITGB3ITGA2BTGM2F13A1TGM1 | |
| SCHEMBL13702142 | 0.85 | TLR2 (0.53) | ITGB3ITGA2BTGM2F13A1TGM1 | |
| SCHEMBL28406498 | 0.85 | KLK7 (0.47) | ITGB3ITGA2BTLR2TLR1KLK7 | |
| SCHEMBL28406503 | 0.85 | ITGB3 (0.55) | ITGB3ITGA2BTGM2F13A1TGM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11471503-B2 | Use of KOR agonist in combination with MOR agonist in preparing drug for treating pain | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2022-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11471503-B2 | Use of KOR agonist in combination with MOR agonist in preparing drug for treating pain | OPRK1, OPRM1, OPRL1 | ITGB3 2700/4885ITGA2B 1632/4885TGM2 2681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.